spironolactone has been researched along with betadex in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bramley, PN; Chrystyn, H; Losowsky, MS; Swallow, RD; Tuladhar, BR; York, P; Yusuff, NT | 1 |
| Fujinaga, T; Hashimoto, T; Otagiri, M; Seo, H; Tsuruoka, M; Uekama, K | 1 |
| Mannermaa, JP; Schipper, NG; Thompson, DO; Tötterman, AM | 1 |
| Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P | 1 |
| Kaukonen, AM; Lennernäs, H; Mannermaa, JP | 1 |
| Balogh, A; Drávavölgyi, G; Horváthová, T; Marosi, G; Nagy, ZK; Sóti, PL; Vigh, T | 1 |
2 trial(s) available for spironolactone and betadex
| Article | Year |
|---|---|
Improved bioavailability from a spironolactone beta-cyclodextrin complex.
Topics: Adult; beta-Cyclodextrins; Biological Availability; Cyclodextrins; Female; Humans; Male; Powders; Spironolactone; Tablets | 1991 |
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
Topics: beta-Cyclodextrins; Biological Availability; Canrenone; Chronic Disease; Cross-Over Studies; Cyclodextrins; Diuresis; Diuretics; Female; Humans; Liver Diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome; Water-Electrolyte Balance | 1997 |
4 other study(ies) available for spironolactone and betadex
| Article | Year |
|---|---|
Enhancement of oral bioavailability of spironolactone by beta- and gamma-cyclodextrin complexations.
Topics: Animals; beta-Cyclodextrins; Biological Availability; Cyclodextrins; Dextrins; Dogs; gamma-Cyclodextrins; Male; Spironolactone; Starch | 1983 |
Intestinal safety of water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells.
Topics: Administration, Oral; beta-Cyclodextrins; Caco-2 Cells; Cyclodextrins; Diuretics; Humans; Intestines; Mannitol; Microscopy, Fluorescence; Solubility; Solutions; Spironolactone | 1997 |
Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
Topics: Animals; Area Under Curve; beta-Cyclodextrins; Biological Availability; Chemistry, Pharmaceutical; Cyclodextrins; Diuretics; Drug Evaluation, Preclinical; Half-Life; Humans; Infant, Newborn; Infant, Premature; Male; Mineralocorticoid Receptor Antagonists; Pharmaceutical Vehicles; Rats; Rats, Wistar; Solutions; Spironolactone | 1998 |
Polymer-free and polyvinylpirrolidone-based electrospun solid dosage forms for drug dissolution enhancement.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Calorimetry, Differential Scanning; Crystallization; Dosage Forms; Drug Compounding; Mineralocorticoid Receptor Antagonists; Povidone; Powder Diffraction; Solubility; Spectrum Analysis, Raman; Spironolactone; X-Ray Diffraction | 2013 |